#### Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

#### NEUROCRINE BIOSCIENCES INC

Form 4

January 15, 2015

# FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

**OMB** Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

**OMB APPROVAL** 

burden hours per response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * MITCHELL W THOMAS			2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [NBIX]	5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)		
(Last) 12780 EL CAI	(First)  MINO REA	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/13/2015	_X_ Director 10% Owner Officer (give title below) Other (specify below)		
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person		
SAN DIEGO, CA 92130				Form filed by More than One Reporting Person		

(City)	(State)	(Zip) Tabl	e I - Non-E	Derivative	Securi	ities Acqu	ired, Disposed of	, or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securition(A) or Di (Instr. 3,	sposed	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/13/2015		M	15,000	A	\$ 3.07	16,000	D	
Common Stock	01/13/2015		M	15,000	A	\$ 3.4	31,000	D	
Common Stock	01/13/2015		M	15,000	A	\$ 7.05	46,000	D	
Common Stock	01/13/2015		S <u>(1)</u>	45,000	D	\$ 30.07 (2)	1,000	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration Date		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amour or Number of Shar
Nonqualified Stock Option	\$ 3.07	01/13/2015		M	15,000	(3)	05/29/2016	Common Stock	15,00
Nonqualified Stock Option	\$ 3.4	01/13/2015		M	15,000	<u>(4)</u>	05/25/2017	Common Stock	15,00
Nonqualified Stock Option	\$ 7.05	01/13/2015		M	15,000	<u>(5)</u>	05/25/2018	Common Stock	15,00

### **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
MITCHELL W THOMAS 12780 EL CAMINO REAL SAN DIEGO, CA 92130	X						

## **Signatures**

Timothy P. Coughlin, By Power of Attorney 01/15/2015

\*\*Signature of Reporting Person Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted (1) by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from \$29.48 to \$30.77. The (2) Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Reporting Owners 2

#### Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

- (3) The option was granted May 29, 2009 and vested in 12 equal monthly installments beginning June 29, 2009.
- (4) The option was granted May 25, 2010 and vested in 12 equal monthly installments beginning June 25, 2010.
- (5) The option was granted May 25, 2011 and vested in 12 equal monthly installments beginning June 25, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.